This week’s articles highlight how tumor-associated macrophages limit the efficacy of PD-1–targeted checkpoint therapy and show that an anti-inflammatory drug may be used to treat lymphedema.
CANCER IMMUNOTHERAPY
Tug-of-war for anti–PD-1
Arlauckas et al. found that tumor-associated macrophages remove PD-1–blocking antibodies from T cells, thus inactivating them; however, this process may be overcome by inhibiting Fcγ receptors.
INFLAMMATION
Relieving lymphedema
Tian et al. showed that surgery- or chemotherapy-induced lymphedema might be prevented or treated with the anti-inflammatory drug ketoprofen, which inhibits the production of the 5-lipoxygenase metabolite leukotriene B4 (LTB4) and consequently may activate Notch signaling.
